Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028

Abstract
Apex Market Research has published a new report titled ”Global Beta-lactam and Beta-lactamase Inhibitors Market share, forecast data, In-Depth Analysis, and Forecast, 2020-2027”. According to the report, The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% The report offers in-depth insights, revenue details, and other vital information regarding the global Beta-lactam and Beta-lactamase Inhibitors market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027.

Attractive Opportunities in the Beta-lactam and Beta-lactamase Inhibitors market

The report covers an in depth description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter's Five Forces Analysis.
Global Beta-lactam and Beta-lactamase Inhibitors market report offers in-depth insights, revenue details, and other vital information regarding the global Beta-lactam and Beta-lactamase Inhibitors market, and the various trends, drivers, restraints, opportunities, and threats in the target market till year 2027. Hence, it covers the impact of these drivers and restraints on demand for this market during the forecast period.
It provides historical data along with future forecast as well as detailed analysis of market on a global, regional and country level. Important market data of this market is projected in the form of tables, graphics, and pictures. On a regional basis, the market is categorized into five regions that include North America, Europe, Asia Pacific, Latin America, and Middle & East Africa. It analyzes complete scenario of each and every region along with highest shareholder of Beta-lactam and Beta-lactamase Inhibitors market. The major players operating into Beta-lactam and Beta-lactamase Inhibitors Market include: Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Scope Of the Report
Report Parameters Details of Parameter
Market Size 2020-2027
Based Year 2019
Forecast Period Covered 2020-2027
Units for value USD
Covered Segments Drug Class, Disease, Route of Administration
Region Covered North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, and Russia, etc.)
Asia-Pacific (China, Japan, ASEAN, India, and Korea)
The Middle East and Africa (UAE, Egypt, South Africa, Saudi Arabia)
South America (Brazil, Chile, Peru, and Argentina)
This research report categorizes the Beta-lactam and Beta-lactamase Inhibitors market to forecast revenues and analyze trends in each of the following submarkets:

By Drug Class

  • Penicillin
  • Cephalosporin
  • Carbapenem
  • Monobactam
  • Combination
    • Penicillin/Beta Lactamase Inhibitors
    • Cephalosporins/Beta Lactamase Inhibitors
    • Carbapenems/Beta Lactamase Inhibitors

By Disease

  • Urinary Tract Infection (excluding cUTI)
  • Respiratory Infection
  • Skin Infection
  • Complicated Urinary Tract Infection (cUTI)
  • Complicated Intra-Abdominal Infections (cIAI)
  • Nosocomial Pneumonia
    • Hospital Acquired Pneumonia
    • Ventilator Associated Pneumonia
    • Other Nosocomial Pneumonia
  • Blood Stream Infection
  • Other Diseases

By Route of Administration

  • Oral
  • Intravenous
  • Others
By geography, this market has been segregated into five regions with revenue and growth rate of Beta-lactam and Beta-lactamase Inhibitors from 2020 to 2027,
There are 13 chapters to put on view for Beta-lactam and Beta-lactamase Inhibitors Market:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview Chapter 2: Market competition by Manufacturers Chapter 3: Production by Regions Chapter 4: Consumption by Regions Chapter 5: Production, By Types, Revenue and Market share by Types Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications Chapter 7: Complete profiling and analysis of Manufacturers Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10: Marketing Strategy Analysis, Distributors/Traders Chapter 11: Market Effect Factors Analysis Chapter 12: Market Forecast Chapter 13: Beta-lactam and Beta-lactamase Inhibitors Research Findings and Conclusion, Appendix, methodology and data source Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export have been determined using secondary sources and verified primary sources. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report. Industry Chain Analysis Raw Material and Suppliers Equipment and Suppliers Manufacturing Process Manufacturing Cost Structure Manufacturing Plants Distribution Analysis Available Customizations We can also provide customized report as per company's specific needs. We can also provide the customized separate regional or country-level reports, for the specific region as per client requirement.
Chapter 1 Industry Overview 1.1 Beta-lactam and Beta-lactamase Inhibitors Market Overview 1.1.1 Beta-lactam and Beta-lactamase Inhibitors Product Scope 1.1.2 Market Status and Outlook 1.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size and Analysis by Regions (2015-2019) 1.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Status and Outlook 1.2.2 EU Beta-lactam and Beta-lactamase Inhibitors Market Status and Outlook 1.2.3 Japan Beta-lactam and Beta-lactamase Inhibitors Market Status and Outlook 1.2.4 China Beta-lactam and Beta-lactamase Inhibitors Market Status and Outlook 1.2.5 India Beta-lactam and Beta-lactamase Inhibitors Market Status and Outlook 1.2.6 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Status and Outlook 1.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Drug Class
1.3.1 Introduction
1.3.1.1 Market Estimates And Forecast 2015-2027
1.3.2 Penicillin
1.3.2.1 Market Estimates And Forecast By Country, 2015-2027
1.3.3 Cephalosporin
1.3.3.1 Market Estimates And Forecast By Country, 2015-2027
1.3.4 Carbapenem
1.3.4.1 Market Estimates And Forecast By Country, 2015-2027
1.3.5 Monobactam
1.3.5.1 Market Estimates And Forecast By Country, 2015-2027
1.3.2 Combination
1.3.2.1 Penicillin/Beta Lactamase Inhibitors
1.3.2.2 Cephalosporins/Beta Lactamase Inhibitors
1.3.2.3 Carbapenems/Beta Lactamase Inhibitors
1.4 Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Disease
1.4.1 Introduction
1.4.1.1 Market Estimates And Forecast 2015-2027
1.4.2 Urinary Tract Infection (excluding cUTI)
1.4.2.1 Market Estimates And Forecast By Country, 2015-2027
1.4.3 Respiratory Infection
1.4.3.1 Market Estimates And Forecast By Country, 2015-2027
1.4.4 Skin Infection
1.4.4.1 Market Estimates And Forecast By Country, 2015-2027
1.4.5 Complicated Urinary Tract Infection (cUTI)
1.4.5.1 Market Estimates And Forecast By Country, 2015-2027
1.4.6 Complicated Intra-Abdominal Infections (cIAI)
1.4.6.1 Market Estimates And Forecast By Country, 2015-2027
1.4.2 Nosocomial Pneumonia
1.4.2.1 Hospital Acquired Pneumonia
1.4.2.2 Ventilator Associated Pneumonia
1.4.2.3 Other Nosocomial Pneumonia
1.4.2.4 Blood Stream Infection
1.4.2.5 Other Diseases
1.4.2.6 Market Estimates And Forecast By Country, 2015-2027
1.5 Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Route of Administration
1.5.1 Introduction
1.5.1.1 Market Estimates And Forecast 2015-2027
1.5.2 Oral
1.5.2.1 Market Estimates And Forecast By Country, 2015-2027
1.5.3 Intravenous
1.5.3.1 Market Estimates And Forecast By Country, 2015-2027
1.5.4 Others
1.5.4.1 Market Estimates And Forecast By Country, 2015-2027
Chapter 2 Global Beta-lactam and Beta-lactamase Inhibitors Competition Analysis by Players 2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size (Million USD) by Players (2015-2019) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future Chapter 3 Company (Top Players) Profiles and Key Data 3.1 Abbott Laboratories 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Abbott Laboratories, Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.1.5 Recent Developments 3.2 Allergan Plc. 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Allergan Plc., Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.2.5 Recent Developments 3.3 F. Hoffmann-La Roche Ltd. 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 F. Hoffmann-La Roche Ltd., Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.3.5 Recent Developments 3.4 GlaxoSmithKline plc 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 GlaxoSmithKline plc, Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.4.5 Recent Developments 3.5 Merck & Co. Inc. 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Merck & Co. Inc., Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD)(2015-2019) 3.5.5 Recent Developments 3.6 Mylan N.V. 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Mylan N.V., Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD)(2015-2019) 3.6.5 Recent Developments 3.7 Novartis International AG (Sandoz) 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Novartis International AG (Sandoz), Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD)(2015-2019) 3.7.5 Recent Developments 3.8 Pfizer Inc. 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Pfizer Inc., Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.8.5 Recent Developments 3.9 Sanofi 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Sanofi, Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.9.5 Recent Developments 3.10 Teva Pharmaceutical Industries Ltd. 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Teva Pharmaceutical Industries Ltd., Beta-lactam and Beta-lactamase Inhibitors Revenue (Million USD) (2015-2019) 3.10.5 Recent Developments Chapter 4 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Type (2015-2019) 4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type (2015-2019) Chapter 5 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Application (2015-2019) 5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) 5.2 Potential Application of Beta-lactam and Beta-lactamase Inhibitors in Future 5.3 Top Consumer / End Users of Beta-lactam and Beta-lactamase Inhibitors Chapter 6 North America Beta-lactam and Beta-lactamase Inhibitors Development Status and Outlook 6.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size (2015-2019) 6.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) Chapter 7 EU Beta-lactam and Beta-lactamase Inhibitors Development Status and Outlook 7.1 EU Beta-lactam and Beta-lactamase Inhibitors Market Size (2015-2019) 7.2 EU Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) Chapter 8 Japan Beta-lactam and Beta-lactamase Inhibitors Development Status and Outlook 8.1 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size (2015-2019) 8.2 Japan Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) Chapter 9 China Beta-lactam and Beta-lactamase Inhibitors Development Status and Outlook 9.1 China Beta-lactam and Beta-lactamase Inhibitors Market Size and Forecast (2015-2019) 9.2 China Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) Chapter 10 India Beta-lactam and Beta-lactamase Inhibitors Development Status and Outlook 10.1 India Beta-lactam and Beta-lactamase Inhibitors Market Size and Forecast (2015-2019) 10.2 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) Chapter 11 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Development Status and Outlook 11.1 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size and Forecast (2015-2019) 11.2 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2015-2019) Chapter 12 Market Forecast by Regions and Application (2020-2027) 12.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size (Million USD) by Regions (2020-2027) 12.1. North America Beta-lactam and Beta-lactamase Inhibitors Revenue and Growth Rate (2020-2027) 12.1.2 EU Beta-lactam and Beta-lactamase Inhibitors Revenue and Growth Rate (2020-2027) 12.1.3 China Beta-lactam and Beta-lactamase Inhibitors Revenue and Growth Rate (2020-2027) 12.1.4 Japan Beta-lactam and Beta-lactamase Inhibitors Revenue and Growth Rate (2020-2027) 12.1.5 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Revenue and Growth Rate (2020-2027) 12.1.6 India Beta-lactam and Beta-lactamase Inhibitors Revenue and Growth Rate (2020-2027) 12.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application (2020-2027) Chapter 13 Beta-lactam and Beta-lactamase Inhibitors Market Dynamics 13.1 Beta-lactam and Beta-lactamase Inhibitors Market Opportunities 13.2 Beta-lactam and Beta-lactamase Inhibitors Challenge and Risk 13.2.1 Competition from Opponents 13.2.2 Downside Risks of Economy 13.3 Beta-lactam and Beta-lactamase Inhibitors Market Constraints and Threat 13.3.1 Threat from Substitute 13.3.2 Government Policy 13.3.3 Technology Risks 13.4 Beta-lactam and Beta-lactamase Inhibitors Market Driving Force 13.4.1 Growing Demand from Emerging Markets 13.4.2 Potential Application Chapter 14 Market Effect Factors Analysis 14.1 Technology Progress/Risk 14.1.1 Substitutes 14.1.2 Technology Progress in Related Industry 14.2 Consumer Needs Trend/Customer Preference 14.3 External Environmental Change 14.3.1 Economic Fluctuations 14.3.2 Other Risk Factors Chapter 15 Research Finding /Conclusion Chapter 16 Methodology and Data Source 16.1 Methodology/Research Approach 16.1.1 Research Programs/Design 16.1.2 Market Size Estimation 16.1.3 Market Breakdown and Data Triangulation 16.2 Data Source 16.2.1 Secondary Sources 16.2.2 Primary Sources 16.3 Disclaimer 16.4 Author List
2815

1550

OUR CLIENT